What does Arcus Biosciences do and what are its main business segments?

What is Arcus Biosciences's latest dividend and current dividend yield?

What is Arcus Biosciences's gross profit margin?

What factors drove the changes in Arcus Biosciences's revenue and profit?

What is the revenue and EPS growth rate for Arcus Biosciences year over year?

What were the key takeaways from Arcus Biosciences’s earnings call?

What guidance did Arcus Biosciences's management provide for the next earnings period?

What is the market's earnings forecast for Arcus Biosciences next quarter?

- **Casdatifan leadership**: Phase III PEAK-1 enrollment on track; frontline TKI-free regimen shows 9% primary progression rate. 
- **Market potential**: $5B peak sales for casdatifan in RCC; 2026 ASCO GU data validates HIF-2 alpha class. 
- **Financial strength**: $1.0B cash runway to H2 2028; 2026 revenue guidance $45-55M. 
- **Pipeline momentum**: Immunology programs entering clinic; HCC expansion under evaluation.

**【CEO Summary Section】**
- Emphasized casdatifan as the best-in-class HIF-2 alpha inhibitor for clear cell renal cell carcinoma (ccRCC). 
- Phase III PEAK-1 study (casdatifan + cabozantinib) targeting IO-experienced ccRCC expected to complete enrollment by end-2026. 
- Frontline strategy focuses on TKI-free regimen (casdatifan + anti-PD-1), with low primary progression rate (9% in early data). 
- Expansion into hepatocellular carcinoma (HCC) under evaluation.

**【CFO Financial Commentary】**
- Cash position: $1.0 billion as of Q4 2025, enabling operations until H2 2028. 
- 2026 GAAP revenue guidance: $45-55 million (driven by Gilead collaboration). 
- R&D expenses expected to decrease meaningfully vs. 2025, contingent on STAR-121 futility analysis.

**【Q&A Highlights】**
- **First-line strategy**: Casdatifan + anti-PD-1 backbone aims to reduce primary progression rate (currently 20-25% for ipi/nivo) and improve PFS. 
- **Market opportunity**: $5 billion peak sales potential for casdatifan in first- and second-line RCC. 
- **Partnerships**: Open to clinical collaborations for non-core mechanisms, retaining 100% rights outside Japan/SE Asia. 
- **Immunology pipeline**: MRGPRX2 antagonist (chronic urticaria/atopic dermatitis) and TNF inhibitor expected in clinic by H1 2027.

Arcus Biosciences, Inc.(RCUS)-20260226-2025 Q4 Earnings call transcript

- **CAS Leadership in RCC**: Phase III PEAK 1 trial with CAS + cabo targeting 700 patients, expected to read out before Merck's LITESPARK-11 (2027), with superior efficacy vs. belzutifan (ORR 30%+ vs. 18-22%).
- **Financial Strength**: $1B cash runway, 2025 peak dev spend ($500M), declining in 2026-2027 as trials near readouts.
- **Market Opportunity**: $5B potential for CAS in IO-naive and IO-experienced settings, with CAS + volorutamig as first TKI-free first-line option.
- **Strategic Focus**: Displacing TKIs in earlier lines with CAS-based regimens, e.g., CAS + Zim in first-line all-comer RCC.


**【CEO Summary Section】**
- CAS is the top priority with Phase III trial PEAK 1 targeting CAS + cabo in IO-experienced patients, expected to enroll 700 patients quickly due to cabo's clinician preference and CAS's safety profile.
- Strong cash position of $1B supports long-term runway, with 2025 as peak development expense year, declining in 2026-2027.
- Vision to displace TKIs in earlier lines with TKI-free regimens, e.g., CAS + AstraZeneca's volorutamig in first-line RCC.

**【CMO Clinical Update】**
- CAS monotherapy data in late-line clear cell RCC show superior ORR (30%+ vs. belzutifan's 18-22%), DCR (80%+ vs. 61%), and PFS (median 9.7-13 months vs. 5.6 months for belzutifan).
- ASCO 2025 will present CAS + cabo safety and efficacy in 40+ patients, with ORR for 25+ patients eligible for 2+ scans.
- Phase III trial PEAK 1 uses 100mg QD CAS + cabo, with PFS as primary endpoint, expected to read out before Merck's LITESPARK-11 (2027).

**【CFO Financial Overview】**
- Q1 2025 cash: $1B (up from $992M in Q4 2024) after $150M equity raise.
- GAAP revenue: $28M (Q1) / $75-90M (FY25), driven by Gilead collaboration.
- R&D expenses: $122M (Q1) / ~$500M (FY25), declining post-2025 as DOM, quemli, and CAS trials near readouts.

**【Q&A Key Points】**
- CAS + cabo combo safety and efficacy data at ASCO 2025 will include waterfall plots and PD rates, with potential for future head-to-head vs. TKIs.
- Market opportunity for CAS in IO-naive and IO-experienced settings: ~$5B (13,000 U.S. / 20,000 ex-U.S. patients in each line).
- No immediate plans for commercialization partnerships; focus on U.S. launch with potential European collaboration.
- Inflammation/immunology pipeline updates expected late 2025, targeting validated but challenging targets.


Actual									-0.63	-0.93	0.03	-0.82	-1.08	-1.09	-1.11	3.71	-0.96	-0.93	-0.9	-0.93	-1.09	-1.04	-0.94	-1.08	-0.05	-1.02	-1	-1.03	-1.14	0	-0.89
Forecast									-0.5618	-0.5814	0.2766	-0.736	-0.8559	-0.874	-1.0571	-1.0938	-0.8544	-0.9412	-1.0384	-1.1394	-1.1636	-1.0983	-1.1294	-1.0246	-1.0099	-1.115	-1.0563	-1.2487	-1.031	-1.1261	-1.1063
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12.14%	-59.96%	-89.15%	-11.41%	-26.18%	-24.71%	-5.00%	+439.18%	-12.36%	+1.19%	+13.33%	+18.38%	+6.33%	+5.31%	+16.77%	-5.41%	+95.05%	+8.52%	+5.33%	+17.51%	-10.57%	+100.00%	+19.55%

RCUS

RCUS fundamentals

RCUS Q4 2025 Earnings

Earnings Call

You can ask Aime

RCUS

RCUS fundamentals

RCUS Q4 2025 Earnings

Earnings Call

RCUS Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

RCUS Earnings Call Summary for Q2/20254:05 PM on Aug 6, 2025

RCUS Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

RCUS Earnings Call Summary for Q4/2024 Apr 1, 2026

RCUS Earnings Call Summary for Q3/20245:00 PM on Nov 6, 2024

You can ask Aime